Instructions to Authors

Chinese Journal of Experimental Ophthalmology (CJEO) supports the ethical principles set out by the Committee on Publication Ethics (COPE). All journal stakeholders and authors are required to observe high standards with respect to publication ethics as set out by the Committee on Publication Ethics (COPE) and International Committee of Medical Journal Editors (ICMJE).

Chinese Journal of Experimental Ophthalmology (CJEO) publishes articles of a broad ranging scope of topics relevant to clinical studies, basic and experimental ophthalmic research, clinical translation of basic and experimental studies. The published scope includes ophthalmic genetic researches, ophthalmic epigenetics, stem cell transplantation for hereditary eye diseases, ophthalmic pharmacology research, ophthalmic immunology, application of artificial intelligence in ophthalmology, molecular biology studies of eye diseases, advances in diagnosis and treatment of eye diseases.

CJEO publishes Editorial, Original articles (basic research, clinical research), review articles, case reports and short communications.

Full research manuscripts should be as concise as possible. For studies on humans, a clear statement concerning informed consent must be provided, and that the study was conducted with Human Experimentation Review by the relevant committee. Original articles should fit within the categories described below and meet the editorial standards stated.

Commentaries presenting interesting and controversial topics in relative research, hypotheses, methods and applications also are welcomed, and these are intended as discussion points and to stimulate new ideas for further study.

The journal offers fast track publication for original articles presenting superior novel findings and for the studies of greatest priority ranked against similar submissions. “Fast track” articles publish earlier than regular manuscripts. Fast Track manuscripts are identified by the editorial board and by reviewer recommendation.

 

2020 (226)

2019 (807)